Janus Henderson Group PLC Purchases 336,209 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Janus Henderson Group PLC grew its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 30.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,456,740 shares of the company's stock after purchasing an additional 336,209 shares during the period. Janus Henderson Group PLC owned about 2.83% of Spyre Therapeutics worth $33,927,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Jefferies Financial Group Inc. lifted its holdings in shares of Spyre Therapeutics by 167.6% during the 4th quarter. Jefferies Financial Group Inc. now owns 1,216,954 shares of the company's stock valued at $28,331,000 after purchasing an additional 762,147 shares in the last quarter. Deutsche Bank AG raised its holdings in Spyre Therapeutics by 46.1% during the 4th quarter. Deutsche Bank AG now owns 31,418 shares of the company's stock worth $731,000 after buying an additional 9,910 shares during the period. Deerfield Management Company L.P. Series C bought a new position in Spyre Therapeutics in the fourth quarter valued at approximately $10,476,000. Driehaus Capital Management LLC lifted its stake in Spyre Therapeutics by 308.1% in the fourth quarter. Driehaus Capital Management LLC now owns 2,803,655 shares of the company's stock valued at $65,269,000 after buying an additional 2,116,575 shares in the last quarter. Finally, Braidwell LP boosted its holdings in shares of Spyre Therapeutics by 17.7% in the fourth quarter. Braidwell LP now owns 2,578,404 shares of the company's stock valued at $60,025,000 after buying an additional 388,568 shares during the period. 80.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SYRE has been the topic of a number of research analyst reports. Leerink Partnrs upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a report on Tuesday, April 8th. Wolfe Research initiated coverage on Spyre Therapeutics in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $27.00 price target on the stock. Leerink Partners assumed coverage on Spyre Therapeutics in a report on Tuesday, April 8th. They issued an "outperform" rating and a $45.00 price target on the stock. Wedbush reiterated an "outperform" rating and set a $65.00 price objective on shares of Spyre Therapeutics in a report on Monday, May 5th. Finally, The Goldman Sachs Group raised Spyre Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 18th. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, Spyre Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $53.40.

Spyre Therapeutics Price Performance

NASDAQ:SYRE traded up $0.29 on Tuesday, hitting $15.17. 44,704 shares of the company's stock were exchanged, compared to its average volume of 610,503. The firm has a 50-day moving average price of $14.84 and a 200-day moving average price of $21.17. Spyre Therapeutics, Inc. has a 52 week low of $10.91 and a 52 week high of $40.26. The company has a market cap of $914.39 million, a P/E ratio of -2.04 and a beta of 2.78.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.02. On average, research analysts expect that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current fiscal year.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).